Triple Therapy Combination Shows Promise for Rare Blood Cancer BPDCN with High Response Rates
Key Insights
A phase 2 trial demonstrated that combining tagraxofusp, azacitidine, and venetoclax achieved an 88% complete response rate in previously untreated BPDCN (search) patients and 64% in relapsed/refractory cases.
The triplet therapy enabled 63% of first-line patients and 55% of relapsed/refractory patients to proceed directly to allogeneic stem cell transplant, a critical treatment option for this aggressive cancer.
The combination showed improved safety profile with reduced capillary leak syndrome (search) rates compared to single-agent tagraxofusp, requiring only 3 days of tagraxofusp administration versus the standard 5-day regimen.
A novel three-drug combination therapy has demonstrated remarkable efficacy in treating blastic plasmacytoid dendritic cell neoplasm (search) (BPDCN (search)), a rare and aggressive blood cancer with limited treatment options. The phase 2 trial results, presented at the 2025 ASH Annual Meeting, showed that combining tagraxofusp (Elzonris) with azacitidine (Vidaza) and venetoclax (Venclexta) achieved high complete response rates while potentially improving the safety profile compared to standard therapy.
High Response Rates Across Patient Populations
The study enrolled 27 patients with either previously untreated (n=16) or relapsed/refractory BPDCN (search) (n=11). In the first-line treatment group, the composite complete response rate reached 88% at a median follow-up of 16.7 months. This included 50% achieving complete response (CR), 38% achieving CR with incomplete hematologic recovery (CRi), and no clinical CRs. The overall response rate was 94%, with one patient achieving partial response.
For patients with relapsed/refractory disease, the composite CR rate was 64%, comprising 9% CR, 36% CRi, and 18% clinical CR rates. The overall response rate consisted entirely of complete responses, with 27% of patients achieving stable disease and 9% experiencing disease progression.
Enhanced Transplant Eligibility
A particularly significant finding was the high proportion of patients who proceeded to allogeneic stem cell transplant, a potentially curative treatment for BPDCN (search). Among first-line patients, 63% went directly to transplant, including 10 of the 11 patients aged 75 or older. In the relapsed/refractory group, 55% proceeded to transplant, demonstrating the regimen's ability to bridge patients to this critical therapeutic intervention.
Improved Safety Profile
The triplet combination showed a favorable safety profile with manageable toxicity. The rate of capillary leak syndrome (search) (CLS), a serious side effect associated with tagraxofusp, was 14.8% overall - equivalent or lower than historical data for single-agent tagraxofusp. Grade 2 and 3 CLS occurred in 11.1% and 3.7% of patients respectively, with no grade 4 or 5 events reported. All CLS events occurred in cycle 1 and were manageable with albumin and diuresis.
The most common grade 3 or higher treatment-related adverse events included thrombocytopenia (63%), decreased white blood cell count (59%), neutropenia (48%), anemia (19%), and hypoxia (11%). No cases of veno-occlusive disease were reported, and the all-cause mortality rates at 30 and 60 days were 3.7% and 7.4%, respectively.
Scientific Rationale and Treatment Protocol
The combination was designed based on laboratory findings showing that tagraxofusp resistance in BPDCN (search) is mediated by DNA methylation and silencing of diphthamide genes necessary for diphtheria toxin cytotoxicity. Azacitidine can reverse this resistance, while BPDCN shows high dependence on BCL2 (search) and sensitivity to venetoclax.
Patients received 12 μg/kg of tagraxofusp on days 4-6, 75 mg/m² of azacitidine on days 1-7, and 400 mg of venetoclax on days 1-21 for each 28-day cycle. Notably, the regimen required only 3 days of tagraxofusp administration compared to the standard 5-day regimen, potentially reducing monitoring requirements.
Survival Outcomes
For previously untreated patients, median overall survival, progression-free survival, and duration of response were not reached. The 2-year progression-free survival and overall survival rates were 65% and 53%, respectively. In the relapsed/refractory group, median overall survival was 8.4 months with median progression-free survival of 6.3 months.
Clinical Significance
"The addition of agents like azacitidine and venetoclax [to tagraxofusp] is attractive because it can have activity in those diseases that may not be as high with tagraxofusp alone," stated lead study author Andrew A. Lane, MD, PhD, director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (search) Center at Dana-Farber Cancer Center (search). "We think [that this triplet] is an effective new treatment option for patients with BPDCN (search)."
The study population had a median age of 70 years, with 93% being male and 30% having skin-only disease. Notably, 37% of patients had prior or concomitant hematologic malignancies, highlighting the complex nature of BPDCN (search) and the need for treatments that can address multiple disease mechanisms.
This triplet combination represents a potential advancement in BPDCN (search) treatment, offering improved response rates, enhanced transplant eligibility, and a more manageable safety profile compared to existing options. The results suggest this approach could become a new treatment standard for this challenging malignancy.